Skip to main content
Fig. 3 | BMC Medical Research Methodology

Fig. 3

From: Optimal designs for phase II/III drug development programs including methods for discounting of phase II results

Fig. 3

Optimization results. Maximal expected utility u, corresponding optimal design parameters \( {\delta}^{\ast }=\left({d}_2^{\ast },{HR}_{go}^{\ast}\right) \), \( {\delta}^{\ast }=\left({d}_2^{\ast },{HR}_{go}^{\ast },{\lambda}^{\ast}\right) \) or \( {\delta}^{\ast }=\left({d}_2^{\ast },{HR}_{go}^{\ast },{\alpha}_{CI}^{\ast}\right) \), expected probability to go to phase III \( {p}_{go}^{\ast } \), expected probability of a successful program sP, expected estimate used for sample size calculation \( {\varepsilon}_2^{\ast } \), expected number of events in phase III when going to phase III \( {d}_3^{\ast } \) and expected total number of events of program d in the optimal design, for c2 = 0.75, c3 = 1, c02 = 100, c03 = 150 in $ 105, ξ2 = ξ3 = 0.7, 1 − β = 0.9, α = 0.025 (one sided), for program set-ups \( S\left({\hat{\theta}}_2^{s_1},{\hat{\theta}}_2^{s_2}\right) \), s1, s2 = λ, αCI or u (that is \( S\left({\hat{\theta}}_2^u,{\hat{\theta}}_2^u\right) \): black circle; \( S\left({\hat{\theta}}_2^u,{\hat{\theta}}_2^{\lambda}\right) \), \( S\left({\hat{\theta}}_2^{\lambda },{\hat{\theta}}_2^{\lambda}\right) \): green cross; \( S\left({\hat{\theta}}_2^u,{\hat{\theta}}_2^{\alpha_{CI}}\right) \), \( S\left({\hat{\theta}}_2^{\alpha_{CI}},{\hat{\theta}}_2^{\alpha_{CI}}\right) \): violet triangle), benefit scenarios bs 1–7, and weights for the prior distribution w = 0.3, 0.6, 0.9, where the yellow line indicates \( \exp \left(-\mathrm{E}\left[{\hat{\theta}}_2\right]\right) \). Note that the symbols used to show the program characteristics of both multiplicatively and additively adjusted program set-ups, i.e., green crosses and violet triangles, appear as stars when plotted on top of each other

Back to article page